Tag Archives: Michael Wiederhorn

CVS Health (CVS) Gets a Hold Rating from Oppenheimer

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Hold rating on CVS Health (CVS – Research Report). The company’s shares opened today at $56.85. Wiederhorn wrote: “CVS reported $1.62, compared to OPCO/Street of $1.50. Adjusted results exclude

Humana Inc (HUM) Receives a Buy from Oppenheimer

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana Inc (HUM – Research Report), with a price target of $373. The company’s shares closed yesterday at $255.41. Wiederhorn observed: “HUM reported Q1:19 adj. EPS

Oppenheimer Sticks to Its Buy Rating for Community Health (CYH)

In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health (CYH – Research Report), with a price target of $5. The company’s shares closed yesterday at $3.44. Wiederhorn noted: “CYH reported Q1:19 adj-EBITDA of

Oppenheimer Thinks UnitedHealth’s Stock is Going to Recover

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on UnitedHealth (UNH – Research Report), with a price target of $305. The company’s shares closed yesterday at $230.20, close to its 52-week low of $220.77. Wiederhorn

Analysts Offer Insights on Services Companies: Cigna Corp (NYSE: CI) and Hibbett Sports (NASDAQ: HIBB)

There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on Cigna Corp (CI – Research Report) and Hibbett Sports (HIBB – Research Report) with bullish sentiments. Cigna Corp (CI) Oppenheimer analyst Michael

Oppenheimer Keeps a Buy Rating on Amedisys (AMED)

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Amedisys (AMED – Research Report). The company’s shares opened today at $125.18. According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of